Previous 10 | Next 10 |
2024-03-20 08:15:10 ET More on Taysha Gene Therapies Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation Taysha: Produces Solid Data But Has Abandoned Programs Taysha t...
2024-03-20 05:09:48 ET DENVER, Colo., Mar 20, 2024 ( 247marketnews.com )- Taysha Gene Therapies, Inc. (NASDAQ: TSHA ) reported, after yesterday’s market close, its full year 2023 financial results and provided corporate and clinical updates. “We are highly encourag...
2024-03-19 21:04:06 ET Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Conference Call March 19, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director, Head of Corporate Communications and Investor Relations Sean Nolan - Chief Executive Officer Suk...
2024-03-19 17:37:35 ET Gainers: Taysha Gene Therapies ( TSHA ) +32% . Canopy Growth Corporation ( CGC ) +14% . Sarcos Technology and Robotics ( STRC ) +12% . Adicet ( ACET ) +6% . Bridger Aerospace Group Holdings ( BAER ) +4%...
2024-03-19 16:10:43 ET More on Taysha Gene Therapies Taysha: Produces Solid Data But Has Abandoned Programs Taysha transfers rights to 3 programs, extends cash runway into 2026 Seeking Alpha’s Quant Rating on Taysha Gene Therapies Historical earnings d...
Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x10 14 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement i...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
2024-03-18 17:35:35 ET More on Taysha Gene Therapies Taysha: Produces Solid Data But Has Abandoned Programs Taysha transfers rights to 3 programs, extends cash runway into 2026 Seeking Alpha’s Quant Rating on Taysha Gene Therapies Historical earnings d...
2024-03-18 17:35:27 ET More on etc. A Bitcoin Strategy Using The 200-Day Simple Moving Average (Technical Analysis) Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Re-Emerging Markets Biggest stock movers today: NVDA, GOOG, FOUR and more ...
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS...
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x10 15 total vg) with dosing...
DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it...
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support t...